Device Trial Radar · NCT03618095
REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects
Last checked: Nov 20, 2026Latest source record: Dec 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
382
Actual
Start
Jan 14, 2019
Primary completion
Mar 30, 2021
Study completion Mar 31, 2021
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Aug 7, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects
Conditions
- Aortic Valve Stenosis
Interventions
LOTUS Edge Valve SystemDevice
TAVR with the LOTUS Edge Valve System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of All-cause Mortality and All Stroke.Time frame: 1 year post index procedure and device implantation
Locations
50 sites in 2 countries. Site status is shown where the registry gives one.
Huntsville Hospital
Huntsville, Alabama
Tucson Medical Center
Tucson, Arizona
Arkansas Heart Hospital
Little Rock, Arkansas
47 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.